Literature DB >> 16379035

Serum IGF-1 in treated acromegaly - how normal is "normal"?

Cecilia Lansang1, Nikoloz Chitaia, Nicholas E Simpson, Laurence Kennedy.   

Abstract

We describe four acromegalic patients with persisting typical symptoms - excessive sweating, lack of suppleness of hands, joint pains - despite the achievement of normal serum IGF-1 levels after pituitary surgery. In three patients there was a clear improvement in symptoms when lower IGF-1 levels within the normal range were achieved with pegvisomant treatment. In the fourth patient IGF-1 levels have fluctuated within the normal range with persistence of abnormal sweating, particularly at night. Two of three patients who had an oral glucose tolerance test when serum IGF-1 was in the normal range failed to suppress GH levels to less than 1 ng/ml. We conclude that, in the treated acromegalic patient, IGF-1 levels within the normal range need to be looked at critically to determine what is truly normal for that individual. Relief of symptoms seems a reasonable yardstick, in addition to population norms, by which to judge whether the prevailing IGF-1 level is appropriate; in some cases the aim should be an IGF-1 level in the lower half of the normal range, or perhaps even the lowest quartile.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16379035     DOI: 10.1007/s11102-005-4241-z

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  13 in total

Review 1.  Criteria for cure of acromegaly: a consensus statement.

Authors:  A Giustina; A Barkan; F F Casanueva; F Cavagnini; L Frohman; K Ho; J Veldhuis; J Wass; K Von Werder; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

2.  Biochemical monitoring of disease activity after surgery for acromegaly.

Authors:  S M Shalet
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

3.  Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease.

Authors:  Stig Andersen; Klaus Michael Pedersen; Niels Henrik Bruun; Peter Laurberg
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

4.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

5.  Factors influencing mortality in acromegaly.

Authors:  Ian M Holdaway; Raja C Rajasoorya; Greg D Gamble
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

6.  Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.

Authors:  Pamela U Freda; Abu T Nuruzzaman; Carlos M Reyes; Robert E Sundeen; Kalmon D Post
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

7.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

8.  Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly.

Authors:  Catherine Beauregard; Uyen Truong; Jules Hardy; Omar Serri
Journal:  Clin Endocrinol (Oxf)       Date:  2003-01       Impact factor: 3.478

9.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.

Authors:  P U Freda; K D Post; J S Powell; S L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

View more
  1 in total

1.  Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.

Authors:  Aart J van der Lely; Roy Gomez; Andreas Pleil; Xavier Badia; Thierry Brue; Michael Buchfelder; Pia Burman; David Clemmons; Ezio Ghigo; Jens Otto Lunde Jørgensen; Anton Luger; Joli van der Lans-Bussemaker; Susan M Webb; Christian J Strasburger
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.